NRG Therapeutics Ltd. has been awarded a grant from Target ALS Foundation to support its discovery program for a treatment for amyotrophic lateral sclerosis (ALS).
Acurastem Inc. has secured $4 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to facilitate the development of its UNC13A program toward clinical trials for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Mestag Therapeutics Ltd. has been awarded a £1.5 million ($1.9 million) grant from Innovate UK’s Cancer Therapeutics program to accelerate the development of MST-0300.
Eydisbio Inc. has been awarded a $2.6 million phase II Small Business Innovation Research (SBIR) grant from the National Institute of Health’s (NIH) National Heart, Lung, and Blood Institute (NHLBI) to support its ongoing research into the efficacy of TAK1 inhibition in animal models of systemic sclerosis.
Anivive Lifesciences Inc., a One Health technology company, reported the NIH’S National Institute of Allergy and Infectious Diseases (NIAID) has awarded grant funding worth up to $33 million to the company to support the development of a vaccine against the fungus Coccidioides, which causes Valley Fever.
Medannex Ltd. has been awarded an Innovate UK grant to fund a £313,000 (US$403,000) project developing a new treatment for pediatric osteosarcoma. Innovate UK will fund £231,000 (US$297,000) of the project costs, with the remainder financed by Medannex.
A researcher at Australia’s Children’s Cancer Institute has been awarded a 3-year US$400,000 grant by the Chadtough Defeat DIPG Foundation to develop and test a new drug candidate for diffuse intrinsic pontine glioma (DIPG).